An Open-label, Two-part, Phase 2 Clinical Trial to Investigate the Safety and Diagnostic Performance of uPAR PET Imaging for Non-invasive Classification of ISUP Grades Among Patients With Localised, Untreated Prostate Cancer.
Latest Information Update: 25 Nov 2024
At a glance
- Drugs Copper 64 DOTA AE105 Curasight (Primary)
- Indications Adenocarcinoma; Prostate cancer
- Focus Pharmacokinetics
- Acronyms uTRACE-101
- Sponsors Curasight
Most Recent Events
- 04 Jul 2024 New trial record